A daily compilation of articles, manuscripts, and news focused on the ADC market and compiled for the scientists who are making the cure everyday.
Wednesday, May 15, 2019
ABL Bio has a different kind of business model
Buying and selling technology vital to ABL Bio business model
But maybe they are worth a look because they are taking a different approach to ADC development. Instead of spending the time, effort, and money to build in house proprietary technologies, they are in the business of buying and selling IP. In some cases that looks like the in-licensing deal they have with LegoBio for ADC Linkers, but in others they are out-licensing their own technologies. In the end, they think focusing on technology blocks is a faster way to market.
Are they on to something? And have you seen anything like this before?
- - - [Main]
Subscribe to: Post Comments (Atom)
Post a Comment